The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery

Z Fu, B Huang, J Tang, S Liu, M Liu, Y Ye, Z Liu… - Nature …, 2021 - nature.com
SARS-CoV-2 is the pathogen responsible for the COVID-19 pandemic. The SARS-CoV-2
papain-like cysteine protease (PLpro) has been implicated in playing important roles in virus …

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status

TM Abd El-Aziz, JD Stockand - Infection, Genetics and evolution, 2020 - Elsevier
Coronaviruses are a large group of viruses known to cause illnesses that vary between the
common cold and more severe diseases to include severe acute respiratory syndrome …

Review on COVID‐19 diagnosis models based on machine learning and deep learning approaches

ZAA Alyasseri, MA Al‐Betar, IA Doush… - Expert …, 2022 - Wiley Online Library
COVID‐19 is the disease evoked by a new breed of coronavirus called the severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Recently, COVID‐19 has become a …

Clinical best practice advice for hepatology and liver transplant providers during the COVID‐19 pandemic: AASLD expert panel consensus statement

OK Fix, B Hameed, RJ Fontana, RM Kwok… - …, 2020 - Wiley Online Library
Background and Aims Coronavirus disease 2019 (COVID‐19), the illness caused by the
SARS‐CoV‐2 virus, is rapidly spreading throughout the world. Hospitals and healthcare …

Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers

AHJ Danser, M Epstein, D Batlle - Hypertension, 2020 - Am Heart Assoc
During the spread of the severe acute respiratory syndrome coronavirus-2, some reports of
data still emerging and in need of full analysis indicate that certain groups of patients are at …

[HTML][HTML] The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

L Caly, JD Druce, MG Catton, DA Jans, KM Wagstaff - Antiviral research, 2020 - Elsevier
Although several clinical trials are now underway to test possible therapies, the worldwide
response to the COVID-19 outbreak has been largely limited to monitoring/containment. We …

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents

V Mody, J Ho, S Wills, A Mawri, L Lawson… - Communications …, 2021 - nature.com
Emerging outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection is a major threat to public health. The morbidity is increasing due to lack of SARS …

Ongoing clinical trials for the management of the COVID-19 pandemic

MP Lythgoe, P Middleton - Trends in pharmacological sciences, 2020 - cell.com
COVID-19 has rapidly developed into a worldwide pandemic with a significant health and
economic burden. There are currently no approved treatments or preventative therapeutic …

SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging

W Rut, K Groborz, L Zhang, X Sun… - Nature chemical …, 2021 - nature.com
In December 2019, the first cases of infection with a novel coronavirus, SARS-CoV-2, were
diagnosed. Currently, there is no effective antiviral treatment for COVID-19. To address this …

The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world …

SP Stawicki, R Jeanmonod, AC Miller… - Journal of global …, 2020 - journals.lww.com
What started as a cluster of patients with a mysterious respiratory illness in Wuhan, China, in
December 2019, was later determined to be coronavirus disease 2019 (COVID-19). The …